Actinium Pharmaceuticals (ATNM) announced that Lynn Bodarky has been named Chief Business Officer to lead the company’s business development, licensing, and collaboration activities. Bodarky joins Actinium with over 25 years of proven business development and licensing experience at large global pharmaceutical and innovative biotechnology companies including Pfizer (PFE), Merck (MRK), Progenics and HiFiBiO. Over her career, she has executed a wide array of business transactions totaling over $5 billion in value across oncology, autoimmune and neurological indications.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ATNM:
- Cantor Fitzgerald biotech analysts to hold an analyst/industry conference call
- H.C. Wainwright sees Actinium Pharmaceuticals as prime candidate for acquisition
- Eli Lilly deal for Point puts radiopharma names in spotlight
- Point Biopharma deal reads positively to radiopharma names, says B. Riley
- Actinium presents updated survival data from Phase 2b trial of Actimab-A
